Western New York Dental Group, Pc | |
800 Harlem Rd Suite 400 W Seneca NY 14224-1083 | |
(716) 824-5857 | |
(716) 824-5890 |
Full Name | Western New York Dental Group, Pc |
---|---|
Speciality | Dentist - General Practice |
Location | 800 Harlem Rd, W Seneca, New York |
Authorized Official Name and Position | Michael D. Ehlers (OWNER) |
Authorized Official Contact | 7168245857 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Western New York Dental Group, Pc 125 Lawrence Bell Dr Suite 102 Williamsville NY 14221-7817 Ph: (716) 634-4679 | Western New York Dental Group, Pc 800 Harlem Rd Suite 400 W Seneca NY 14224-1083 Ph: (716) 824-5857 |
NPI Number | 1255406526 |
---|---|
Provider Enumeration Date | 11/22/2006 |
Last Update Date | 08/22/2020 |
Identifier | Type | State | Issuer |
---|---|---|---|
1255406526 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | 039829 (New York) | Primary |
News Archive
The American College of Radiology (ACR®) has revised the name of the Patient Experience Commission to the ACR Commission on Patient- and Family-Centered Care to better reflect the commission's scope and purpose.
The recent use of genetically modified mice and rats in combination with an animal model of obstructive nephropathy, a type of renal disease, has given researchers new insight in the development of kidney disease.
Exposure to levels of radon gas typically found in 90 percent of American homes appears to reduce the risk of developing lung cancer by as much as 60 percent, according to a study published in the March 2008 issue of the journal Health Physics.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol) tablets.
New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.
› Verified 3 days ago